All right. Welcome, everybody, and thanks for joining us again at Guggenheim's Healthcare Innovation Conference. I'm Seamus Fernandez, one of the Senior Biopharma Analysts here at Guggenheim, and I'm really pleased to be joined again this year by Arcutis Biotherapeutics. To my immediate left is Frank Watanabe, President and CEO, Rob Lisicki, the newly appointed CCO, and Latha Vairavan, CFO. Again, going from left to left to left. Maybe Frank, let's just kind of get started here. It's been a great year, obviously, for Arcutis and ZORYVE. You've raised 2026 guidance twice, and gave it for the first time earlier this year. But in terms of just what's driving the outperformance from your perspective, relative to that original guidance, what is it, and how are you looking forward into 2027?
I think the performance in 2026 really is the same reason we saw strong performance in prior years. I think it's threefold. The first one is the product profile itself. As you know from your doctor talks, this is a product that's very well-suited to what clinicians and patients are looking for, both in terms of efficacy and safety, tolerability, and convenience. So, it's filling a really important need in the marketplace, and that's what's driven, I think, our very, very high share of the branded non-steroidal market. That's factor number one. Factor number two is, I think, as you know, we're dealing in very, very large markets that have been historically dominated by topical steroids, but there's this ongoing shift away from topical steroids because of all the safety concerns with long-term steroid use in these chronic conditions.
Then the third thing, I think the team is, we have an outstanding team. We continue to attract top talent. Rob's addition to the team has been fantastic. We've known each other for decades. Very, very experienced dermatology commercial leader. But, I think across the board, the strength of our team along with the large market and the really differentiated product profile has been what has continued to drive the very strong performance of ZORYVE. I think in 2027, as we look to 2027, that is just going to continue. Then, we have some really important catalysts that we think are going to translate into even further growth in 2027. We expanded the dermatology sales team in 2026. We're starting to see the impact of that now, and I think that'll continue on through 2027. We've started building out the primary care and pediatric team.
We haven't really seen much impact from that yet because it's still very early days. We're only about three months in to the peds and PCP team. But I think in 2027, that'll be an important driver. In addition to that, we signed the recent deal with Simone Biles to be one of our spokespeople. She's a fantastic brand ambassador. We're very excited about her raising awareness about both seborrheic dermatitis and eczema, and ZORYVE as an opportunity, a new opportunity to treat those conditions. Then lastly, we've got the pediatric approval coming up at the end of February, which we think is going to be a really important catalyst for growth in 2027.
You are taking a very strong business with good momentum going into 2027, then you are layering on top of that a number of very important catalysts. That is really what has led us to this confidence, bullishness about 2027 and beyond that we have talked about in some of our previous conversations.
Great. Fourth quarter is seasonally, so far, been consistently the strongest quarter. Is there anything that we should keep in mind about this fourth quarter in particular that could possibly be different in any way, shape, or form? Then should we anticipate the sort of standard seasonality, the dip post-fourth quarter?
Yeah. Nothing to us would suggest that Q4 of 2026 is going to look any different than any other typical Q4. It does tend to be the strongest quarter of the year. The only, I think, comment I would make, just as in Q3, we do not expect to see much in terms of price. We got to our steady state gross-to-net very early this year.
Yeah.
I cannot exactly say why other than patients were spending more on healthcare apparently this year. We very quickly got to steady state, and that is why we did not see much price effect in Q3, and you would not expect to see much price in Q4 either. You should see some nice volume growth.
Okay, great. So, maybe a question for Rob. As you sort of come in with your extensive experience, and the time obviously working on Enbrel with Frank, you called ZORYVE's share so far merely the tip of the iceberg. What really surprised you most when you looked under the hood? What do you see as kind of the untapped near-term opportunities in particular?
Yeah. On the surprise, I'd say two things. One is, externally, it's always hard to measure the esprit de corps of a company. The culture of the company is really special, unique. Everyone has a shared vision and purpose, and companies that have that do perform well. I think on this, the other surprise would be the development success. When you look at the number of phase II, phase III successfully completed studies in such a rapid timeframe, it's hard to find large companies that have that success. On the opportunity piece, I think the iceberg analogy is perfect. When you think of an iceberg, you see 10% of it above the water, 90% is below. That's where we are right now, for branded non-steroidals.
We're going to exit the year with 10% of the market being branded non-steroidal, so 90% of the opportunity is in front of us. The way we get that is through additional indication work. We have studies in vitiligo and HS. We have the AD infant indication coming in March. The other is we announced about a week ago a phase III study in AD moderate to severe. Assuming success with all of those studies, you have an asset that essentially can be used cradle to cane, in the AD space. Regardless of mild, moderate, or severe, regardless of BSA coverage, and regardless of systemic or biologic use, all of those things, I think, offer the product an extremely exciting future.
What are the aspects, Frank, that unlock the opportunity that we've talked about? I think the street continues to not quite get to the $2.5 billion-$3.5 billion. I think mentally, when we just sort of look at the market, one can get there actually pretty easily.
Yep.
But there's this barrier of, "Wow, no topical has done that before." So, what is different this time?
Well, I think-
It helps to have a product that works.
It helps to have a product that works. But no, I think that historically, steroids have been around for 70 years, right? And they're the foundation of dermatology, not just topical dermatology, but dermatology period, because they are effective. And historically, the non-steroidals have not been nearly as effective, as you know, and many of them had tolerability issues. And so, derms kept using the things that worked. And in the last five years, we've seen three new, four new, I guess now, branded non-steroidals come out. Two of them, I think, are very good, including ours. And that's really driving now a discussion in dermatology about, okay, it's time now, we need to start moving away from topical steroids, right? Topical steroids are very effective drugs, and they're safe when they're used as directed, which is for short periods of time. Well, these are chronic diseases, right?
Patients get into safety issues, or they end up having to stop their steroid use. Now they have drugs like ZORYVE that you can use for any duration, for any amount of disease, for a whole variety of different indications. That is really catalyzed this conversation in dermatology around the need to move away from topical steroids. We just saw most recently, I think, the AAD issued new topical guidelines for kids. For the first time, the AAD said in the guidelines, non-steroidals should be preferred over topical steroids because of the long-term safety issues of steroids, right? Finally, the academy has taken a stand on this. In September, there was a multidisciplinary group of physician groups and patient groups that met in Washington to talk about the need for the FDA to update steroid labels, and they have now petitioned the FDA for that to happen.
There is a growing momentum. To Rob's iceberg analogy, last year, derms wrote 16 times more topical steroids than they did branded non-steroidals. You do a quick back-of-the-envelope calculation, it does not take much of a shift for ZORYVE to hit that $2.5 billion-$3.5 billion peak sales that we talked about.
Right. 3.5% penetration right now, and if we are already at-
You get to 15%-20%.
We're already at 500. We're already at five, well, consensus-
Five-
542, 543.
540, yeah. Well over half a billion, right, with 3.5% conversion. There's no reason why we can't get to 15%-20% share, and that delivers $2.5 billion-$3.5 billion peak sales.
Yep. Let's talk about vitiligo. On the recent call, we saw some, I think, really striking evidence of what's possible.
Yep.
Outside of what's possible on sort of individual case reports, what are you hoping to see in the upcoming data, and what sort of drives that step forward into vitiligo? What does it take to convince investors that this is a real opportunity? It seems to us like it's on the cusp of educating the market pretty effectively.
Yeah. First of all, to be clear, I don't think we should expect to see a result similar to what we showed you guys on Q3. If we did, that was a really amazing response and very rapid response. We've seen a number of these case reports published of ZORYVE working in vitiligo. We hear about it anecdotally from doctors. I think importantly, in the AD trial, and especially in the seborrheic dermatitis trial, patients who had post-inflammatory hypopigmentation, we saw that resolve with ZORYVE in a matter of weeks, right?
At eight weeks, almost everyone had resolved their PIH. There's a lot of evidence suggesting that we're working in pigmentary disorders. At the same time, mechanistically, not only are we reducing inflammation the way that, say, a JAK inhibitor would, but there's also quite a bit of science around the role of PDE4s in melanocytes. We think we're probably also promoting melanogenesis at the same time that you're reducing the inflammation. Mechanistically, it makes a ton of sense. We need to see clear evidence that it's working in a reasonable number of patients with a reasonable magnitude in this phase II study to move forward. Not much more than that, right?
Got it.
I think if the drug works, because of all the other advantages of ZORYVE, we're going to be very competitive. If we end up having an efficacy advantage, we work faster, or we have a deeper response, or we're able to capture patients who don't respond to other treatments, then I think we're looking at best-in-class kind of profile for the product. But we won't really know that until we get into phase III.
Commercially, when you think about vitiligo, there's sort of two dynamics that I think offer interesting potential advantages. Number one, not a lot of treatments available.
Right.
Number two. This is absolutely ultra-chronic, as far as I can tell. In that context, can you just remind us where we are on the average number of tubes for existing indications, and then how might this expand that?
Sure. Yes, so what we're seeing with seb derm, psoriasis, and eczema is that patients are going through around two to three units a year.
Yeah.
Which is exactly what we expected, right, at launch. I think we told the street we expected two to three, and that's what we're seeing. Patients tend to use a little more foam than cream. It's easy to dispense, it's easy to spread. I think they probably just consume more, not that they need more of the foam. But we do see that pretty consistently. I think with vitiligo, as with all the diseases, it's really driven by body surface area. The face and the hands are the thing that bother the patients the most, right? So that's the areas they're most likely to treat. You can't cover that up, right? Everyone sees that.
At this point in the game, I do not know that we have any reason to think that it's going to be dramatically more drug than what we see in other diseases, but I would not expect anything dramatically less. There could be some upside in vitiligo, but I think we will have to just see as we get out into the marketplace.
Right. Okay, got it. HS, maybe just the basics of HS and the opportunity for topical in that space.
Yeah, I think HS in some respects, in my mind, is similar to vitiligo, right? We've got now some good biologics that work in HS, but like AD, you're not getting to 100% responses, right, even with a biologic. There's a large opportunity to use topicals adjunctively on top of a 17A/F or on top of a TNF. But also, there are a lot of mild patients that aren't eligible for biologic therapy, but who are going to want to be treated, and I think that's another opportunity for us to play in that arena. Having the foam, I think, is also an important aspect since this is always occurring in the axillae and the groin, and most people don't want to be rubbing creams into their groin and their armpits. So, I think our foam formulation could be a really important differentiator.
Then, like vitiligo, not only is there an anti-inflammatory mechanism with ZORYVE, but PDE4 has been pretty well established to have antifibrotic capabilities as well. roflumilast works in IPF, for example. So, I think that there's a good reason to think that we might have several different mechanisms that we're able to address the HS. And I think investors often forget about the impact of pain and itch in HS, very, very prevalent symptoms.
Everyone focuses on abscesses and nodules because that's the regulatory endpoint, but for the patient, the pain and the itch can be a big factor. And we've shown over and over again that ZORYVE is very effective in itch, we suspect also in pain, probably because PDE4 has an effect on nerve cells and the action potential nerve cells. So, I think we could have, again, a very competitive profile in HS and a unique profile, being able to be used across the severity spectrum, monotherapy or combination therapy with biologics, and in this unique foam formulation.
Yeah, interesting. The pipeline and a product dynamic and the ability to sell effectively with a pipeline and a product, how much does that sort of change the interactions with payers, especially with the context of having both a cream and a foam? How much more does that add to the effectiveness?
Yeah. Rob, you want to take a look?
Yeah, I think there's different rebates between psoriasis and AD. That's really the only kind of difference that I can think of with the payer standpoint. The value, though, from a commercial perspective is the more indications, the more use you have, the more weight you have with a payer.
Volume is a helpful thing. It also helps as new entrants come into the market because it makes it more challenging for them to displace those rebate streams. But across all of the put-ups, it doesn't complicate things. It actually makes things easier for us.
I would say in front of the physician as well.
Yeah.
Right.
Yeah.
Hey, and when you can use ZORYVE on most of the things you see every day, it just becomes part of your armamentarium, becomes a habit at that point.
Right. There is a lot of questions around capital allocation, business development. We did see recently the ZORYVE royalty was acquired by Royalty Pharma from AstraZeneca. Maybe just provide a little context, if you can, for the transaction and the implications, if any, for Arcutis at all.
Latha?
Yeah. I will start with the first part and then go to the AZ royalty. I think our capital allocation strategy is prefaced by what we put out last year at our investor day of growing and expanding ZORYVE and building our pipeline. We have been focused on taking the leverage and the cash flow that we have built this year and investing in the things that we have just talked about, specifically our sales force expansions and our marketing efforts, and continuing to do that, and you will see that inflection into 2027. It is focused on building our pipeline into ARQ-234 and anything that we may do on the BD front. Moving to AZ. AZ, I know we are calling it a sale, but really sort of assigned this royalty to Royalty Pharma.
I think what I want to remind everyone is, one, Royalty Pharma, Frank will say this, I think he said, as he knows the CEO really well, is going to do a good deal. So it really affirms to me the peak sales potential of what ZORYVE can offer and what we said there. It is a 10-year window in which we own the royalty from the start of the launch, and our first launch was in late 2022. So if you kind of take that time horizon and what is left, and you do the math, you will realize that that is in the ballpark of our peak sales.
Okay. Very interesting.
Financially, it has zero impact on us.
Yeah.
We are just-
Right.
Just sending the check to somebody else.
Right. Understood.
To be clear on the peak sales that we said between $2.3 billion - $3.5 billion.
Yes. Yep. Then, in terms of the where you ended Q3, just the cash, you are now cash flow positive, and presumably, is that something that we can assume is likely true from here on out pretty much every quarter going forward?
We said in Q4 of 2025 that we will stay cash flow positive throughout the year, so we have been since late last year into 2026, and our intent is to stay that way in 2027, as we invest. I do not expect to burn money to invest into ZORYVE, but if we do BD or anything, that could change, right?
Yeah.
I would say there may be occasional mismatches between expense and revenue where one quarter we might not generate a lot of cash, but I think over a year, you would expect to see steady accumulation. I do not want to commit to every single quarter, right? March is tough because you have to pay bonus.
Right.
You have non-cash expenses as well.
Yeah.
The trend is very clear, and we have done it now four straight quarters.
Yeah.
I think we are profitable three out of the last four quarters as well, so I think the trajectory.
We have been cash flow positive since last year, and we have had quarters of net income positive, three out of the four, and I expect to stay that way throughout the end of 2026.
Seamus, you followed the company a long time. We are a very disciplined company when it comes to expenses.
Certainly responsible, for sure. In terms of the business development opportunities, you say kind of nice to have but not a necessity. In terms of the You also noted 350 assets reviewed over 10 years, bought two, and the deal flow is rising. What are some of the criteria that you think are key fitting?
This has not changed really since we founded the company 10 years ago. We focus on large markets with high unmet need, right? We do not want to go after satisfied markets. That is generally not a good strategy. We focus on biologically validated targets. It does not have to be that drug, but that mechanism needs to be biologically validated. I do not really like taking biological risk. We look for assets that are really differentiated from other products in the marketplace. Those are fairly high bars, which is why we have done so few deals in spite of the number of drugs we have looked at. I would say the deal flow is increasing. The team is very active looking at assets all the time, always have been.
I think the reason I make the point about this is a nice to have and a must have is we do not have to do business development, right? Given the range of opportunities with ZORYVE and with ARQ-234, we do not have to do anything. The team has a great record of development, as Rob mentioned. If we find an asset and we think there is an opportunity to create shareholder value, I would love to do that deal. What I do not want to do is a stupid deal that ends up destroying shareholder value, right? That is the key to me.
Yep. Understood. One of the assets that you did bring in was ARQ-234. Maybe just talk about how it fits that sort of business development bucket and when may we learn more about that profile?
Yeah. ARQ-234 checked all the boxes. The second box, biologic validation, was the last one to get checked, right? AD is still a large market with still unmet needs in spite of the IL-4/IL-13s. We knew this asset looked to be differentiated from the other assets against this target, and then we saw clinical validation on the target, so we went in and we took out the company. We are very excited about the asset. I think it is a really unique way of addressing AD and potentially other autoimmune disorders.
We are enrolling the phase I multiple ascending dose right now, and as soon as that is done, we are going to be starting a small proof of concept study. We will report out to the street all of the data from the phase I trial when we have the POC data, which will give us an indication of biologic activity, and whether we are going to progress into phase II. If it works in AD, we will probably be looking at other indications as well for this mechanism.
Got it. Great. Just on the IP estate, can you just remind us where the IP estate sits?
Sure.
You have a huge number of patents.
We do.
Yeah.
We have 28, I think, issued patents now. 24 of them are Orange Book listed, as I recall. I do not know. The numbers keep changing all the time because we keep adding. We have patent protection on the cream through 2037. We have patent protection on the foam through 2042. There are four unique patents that only cover the foam. Those range from formulation patents to pharmacokinetic patents to method of use patents. We have multiple different angles of protection for the products. We feel very strongly about our intellectual property estate, and we are always looking for opportunities to expand it.
Got it. Great. Then maybe just to wrap up, if you were to say the one most underappreciated aspect of the story, it kind of feels like you are getting repeatedly validated on the $2.5 billion-$3 billion opportunity, including external e xpensive validation for other players. But how should we be thinking about that?
Yeah, I think the peak sales potential is probably one of the most underappreciated aspects. Look, we're four years in the psoriasis launch. We're 18 months in an AD launch, right? We have multiple products now that we're stacking up. We'll do over $0.5 billion a year this year. This narrative that topicals can't be big, it's been disproven by facts.
Yeah
I think the investment community has to wake up and realize that this is a different world, and that ZORYVE is going to be a multi-billion dollar product.
Yeah. I think my favorite thing is, somebody told me that this product would never be bigger than $400 million, and in year three, we're already north of $500 million and headed to a billion. Congrats on nothing like proving people wrong.
That's right. Thanks a lot, Seamus.
Thanks .
Thank you.
Great to see you.